|
gptkb:Thyroid_Cancer
|
5-year survival rate over 98% for papillary type
|
|
gptkb:unresectable_stage_III_NSCLC
|
5-year survival rate 15-30%
|
|
gptkb:chronic_lymphoid_leukemia
|
5-year survival over 80% (early stage)
|
|
gptkb:HER2-positive_breast_cancer
|
improved with targeted therapy
|
|
gptkb:Philadelphia_chromosome-positive_chronic_myeloid_leukemia
|
5-year survival >80% with treatment
|
|
gptkb:WHO_grade_IV
|
low
|
|
gptkb:Ewing_tumor
|
about 30% (metastatic disease)
|
|
gptkb:Esophageal_cancer
|
5-year survival less than 20%
|
|
gptkb:High-grade_glioma
|
Low
|
|
gptkb:Two-headed_calf
|
low
|
|
gptkb:Conjoined_twins
|
low
|
|
gptkb:Ewing_sarcoma
|
about 70% (localized disease)
|
|
gptkb:leukemia
|
lower in adults
|
|
gptkb:Ewing_tumor
|
about 70% (localized disease)
|
|
gptkb:Two-headed_snake
|
low
|
|
gptkb:Two-headed_calf
|
varies
|
|
gptkb:stage_IV_non-small_cell_lung_cancer
|
low
|
|
gptkb:chronic_lymphoid_leukemia
|
lower in advanced stage
|
|
gptkb:Retinoblastoma
|
over 90% in developed countries
|
|
gptkb:non-small_cell_lung_cancer
|
5-year survival rate varies by stage
|